Answers are grounded in this paper and cite their sources.
To characterize the effect of nipocalimab, a fully human, effectorless IgG1 anti-neonatal Fc receptor (FcRn) monoclonal antibody on immune function.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: